All News
AI meets Rheumatology: ChatGPT and patient response optimization
Large language models, such as ChatGPT, are advanced systems trained on vast amounts of text data, far exceeding what a human can read in a lifetime, to understand and generate human-like language. With these tools at our disposal, they are inevitably making their way into healthcare. One notable example is response optimization for SLE patients, as highlighted in abstract #0989.
Read Article
What is the origin of pain in difficult to manage axSpA?
1- Inflammation
2- Degenerative
3- Central Nervous System
#EULAR2024
NZ https://t.co/KzATnYN4HG
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
Ph III RCT SHR0302 JAK1 selective inhibitor in RA
500+ pts
ACR20 wk 24 SHR0302 8mg & 4mg PBO 75% 70% 40%
ACR70 wk 24 SHR0302 8mg & 4mg PBO 31% 22% 7%
Safety similar other JAKi
Abstr#OP0037 #EULAR24 @RheumNow https://t.co/6ZuvT6czo8
Aurelie Najm AurelieRheumo ( View Tweet)
Digital biomarkers are also going to be useful int he future - from devices such as phone / watches.
Bella Mehta bella_mehta ( View Tweet)
Great 1st #EULAR2024 scientific session: “Asymptomatic” Hyperuricemia — innocent bystander vs. menacing foe. Data re: effects on joints, kidneys, & heart have not supported clear clinical consequences w/ exception of kidney crystal deposition. TIGER Study results eagerly awaited. https://t.co/IPQU3Ww0NA
Links:
Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
Final prep in my hotel room for tomorrow’s big #EULAR2024 opening debate: this David up against the metaphorical (if not physical) Goliath, @Janetbirdope.
Data does not adequately justify this JAKi regulatory safety warning, tomorrow I’ll tell you why. Details below ⬇️
@RheumNow https://t.co/rwFtYRlpLY
David Liew drdavidliew ( View Tweet)
#EULAR204
Encouraging Timeline for future potential treatments for #SLE #Lupus
@LUPUSUK @LupusMadrid @Lupus_Chat @LupusEurope https://t.co/SLKc0XCtFq
Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
Reminder of relevance of #Rheumatoid factor
⬆️RF also predicts
cardiovascular events ⚠️
⬆️disease activity
❗️Worse outcomes
#EULAR2024 #RF #RA https://t.co/kXwh682ONp
Dr Gurdeep S Dulay gurdeep_dulay ( View Tweet)
OP0048 Impressive CLASI (lupus skin index score) with #deucravacitinib - data presented by Dr C Arriens #EULAR24 @RheumNow #WiR https://t.co/EuQdwuolN6
TheDaoIndex KDAO2011 ( View Tweet)
What is new in RA at #EULAR2024?
Below 👇🏻 my article summarising some of the exciting new MoA, therapeutic strategies and drugs that might (or not) shape RA future!
https://t.co/ttYdElWlBY
@RheumNow
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
🚨New(ish) MoA in RA
Abiprubart anti-CD40 mAb
Blocks T cell activation
Reduction DAS28-CRP Wk 12 -2.2 vs. -1.6 PBO
Small sample n=25 per gpe
Safety profile acceptable
To be continued...
Abstr#OP0036 #EULAR2024 @RheumNow https://t.co/su4L7A7nGJ
Aurelie Najm AurelieRheumo ( View Tweet)
Substudy of SELECT-COMPARE trial
Week 60 immunogenicity RZV RA treated UPA 15 mg + MTX
✔️ HUmorale response 71%
✔️ Cellular response 65%
✔️ No serious AEs
✔️ One event of HZ occurred during follow up
Abstr#OP0020 #EULAR2024 @RheumNow https://t.co/8OMwGuIZFx
Aurelie Najm AurelieRheumo ( View Tweet)
Novel B cell depleters! Bispecific T cell engagers (BiTEs) being studied for #SLE & #RA as a way to get CAR-T cell like responses but more accessible w/less risk for CK release syndrome. #EULAR24
T cell-engaging therapies — BiTEs and beyond | Nature Reviews Clinical Oncology
TheDaoIndex KDAO2011 ( View Tweet)
I chaired great debate at #EULAR2025 - JAK Inhibitor Special Warnings: can observational data debunk an RCT? Drs Janet Pope(NO) vs David Liew(YES). Voting suggests most are concerned about JAK warnings, but Liew won by converting a minority his way @janetbirdope @Drdavidliew https://t.co/bV1JdO7c4e
Dr. John Cush RheumNow ( View Tweet)
Nordic country analysis of mortality in RA (n 1145), RA-ILD (239), population ILD (378) & nl controls (1890) shows most mortality in pop ILD (HR 8.3), but less in RA-ILD (HR 3.6). Why is death less in latter; could it be RA therapies? Abstr #POS0022 # EULAR2025 https://t.co/wFZq49rIiW
Dr. John Cush RheumNow ( View Tweet)
✨ Powerful stories shared at the #EULAR2024 Opening Ceremony including from #PARE Chair @fibrofella https://t.co/Jzfk9LrhV4
Mrinalini Dey DrMiniDey ( View Tweet)
EULAR 2024 kicked off with a fantastic debate between Janet Pope and David Liew - ‘JAK inhibitor special warnings: Can observational data debunk an RCT?’
A thought-provoking discussion summarising all aspects of the ongoing conversation on JAKi use in high-risk patients! https://t.co/MzW3jSSCfr
Links:
The Immune-Mediated Inflammatory Disease Forum IMIDforum ( View Tweet)
More data from Jak-pot, the real-world multinational RA study, this time looking at infection in 14 national registries
JAKi (vs TNFi) had no signal for general/serious infection (excluding HZ)
Somewhat reassuring post-ORAL Surveillance infection data
#EULAR2024 OP0092 @RheumNow https://t.co/ocAbc4NiV2
David Liew drdavidliew ( View Tweet)
Extra musculoskeletal manifestations (EMMs) in spondyloarthritis #EULAR2024 OP0085 @RheumNow https://t.co/yRxPmMYLxn
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2024 Please find my article on a preview of interesting abstract to look out for for #lupus #SLE therapies at this year’s congress @RheumNow
https://t.co/TEtrDWq3BF https://t.co/1zIIxsaeL2
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)